Meeting
2011 ASCO Annual Meeting
First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicentre academic phase II study in caucasian patients (pts) (NCT00339586). FIELT study group.
Authors
J. De Greve
Universitair Ziekenhuis Brussels, Brussels, Belgium
J. De Greve , J. P. Van Meerbeeck , J. F. Vansteenkiste , E. Teugels , C. Geers , A. Meert , P. Vuylsteke , C. N. J. Focan , J. Canon , Y. Humblet , G. J. Berchem , B. Colinet , D. Galdermans , L. Bosquée , C. A. Dooms , L. Decoster , J. Vermeij , A. Dewaele , D. C. C. Schallier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Metastatic/Non-small Cell
Track
Lung Cancer
Sub Track
Metastatic
Clinical Trial Registration Number
NCT00339586
Citation
J Clin Oncol 29: 2011 (suppl; abstr 7597)
Abstract #
7597
Poster Bd #
39E
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.
First Author: Julien Mazieres
Poster
2022 ASCO Annual Meeting
A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutation.
First Author: Youngjoo Lee
Poster
2022 ASCO Annual Meeting
A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
First Author: Atsushi Nakamura
Poster
2021 ASCO Annual Meeting
A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER).
First Author: Li Zhang